Quinolone antibiotic for skin and skin structure, lower respiratory and
urinary tract infections and sexually-transmitted diseases. Active against many
gram-positive and gram-negative aerobic bacteria.
Ophthalmic: Treatment of superficial ocular infections involving the
conjunctiva or cornea due to strains of susceptible organisms
Hypersensitivity to ofloxacin or other members of the quinolone group such as
nalidixic acid, oxolinic acid, cinoxacin, norfloxacin, and
Use with caution in patients with epilepsy or other CNS diseases which could
predispose seizures; use with caution in patients with renal impairment; failure
to respond to an ophthalmic antibiotic after 2-3 days may indicate the presence
of resistant organisms, or another causative agent; use caution with systemic
preparation in children <18 years of age due to association of other
quinolones with transient arthropathy; has rarely caused ruptured tendons
(discontinue immediately with signs of inflammation or tendon
1% to 10%:
Cardiovascular: Chest pain (1% to 3%)
Central nervous system: Headache (1% to 9%), insomnia (3% to 7%), dizziness
(1% to 5%), fatigue (1% to 3%), somnolence (1% to 3%), sleep disorders,
nervousness (1% to 3%), pyrexia (1% to 3%), pain
Dermatologic: Rash/pruritus (1% to 3%)
Gastrointestinal: Diarrhea (1% to 4%), vomiting (1% to 3%), GI distress,
cramps, abdominal cramps (1% to 3%), flatulence (1% to 3%), abnormal taste (1%
to 3%), xerostomia (1% to 3%), decreased appetite, nausea (3% to 10%)
Genitourinary: Vaginitis (1% to 3%), external genital pruritus in women
Local: Pain at injection site
Ocular: Superinfection (ophthalmic), photophobia, lacrimation, dry eyes,
stinging, visual disturbances (1% to 3%)
Miscellaneous: Trunk pain
<1%: Syncope, vasculitis, edema, hypertension, palpitations, vasodilation,
anxiety, cognitive change, depression, dream abnormality, euphoria,
hallucinations, vertigo, chills, malaise, extremity pain, weight loss,
paresthesia, ruptured tendons, Tourette's syndrome, weakness, photophobia,
photosensitivity, hepatitis, decreased hearing acuity, tinnitus, cough, thirst
Symptoms of overdose include acute renal failure, seizures, nausea, vomiting
Treatment includes GI decontamination, if possible, and supportive care
Decreased effect: Decreased absorption with antacids containing aluminum,
magnesium, and/or calcium (by up to 98% if given at the same time), iron,
vitamins with minerals, mineral supplements, sucralfate, or didanosine;
fluoroquinolones may be decreased by antineoplastic agents
Increased toxicity/serum levels: Quinolones cause increased caffeine,
warfarin, cyclosporine, procainamide, and possibly theophylline levels.
Cimetidine and probenecid increase quinolone levels.
Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial
enzyme that maintains the superhelical structure of DNA. DNA gyrase is required
for DNA replication and transcription, DNA repair, recombination, and
Absorption: Well absorbed; administration with food causes only minor
alterations in absorption
Distribution: Vd: 2.4-3.5 L/kg
Protein binding: 20%
Half-life, elimination 5-7.5 hours
Elimination: Primarily unchanged in urine
Children >1 year and Adults: Ophthalmic: Instill 1-2 drops in affected
eye(s) every 2-4 hours for the first 2 days, then use 4 times/day for an
additional 5 days
Lower respiratory tract infection: 400 mg every 12 hours for 10 days
Gonorrhea: 400 mg as a single dose
Cervicitis due to C. trachomatis and/or N. gonorrhoeae: 300
mg every 12 hours for 7 days
Skin/skin structure: 400 mg every 12 hours for 10 days
Urinary tract infection: 200-400 mg every 12 hours for 3-10 days
Prostatitis: 300 mg every 12 hours for 6 weeks
Dosing adjustment/interval in renal impairment: Adults: I.V., Oral:
Clcr 10-50 mL/minute: Administer 200-400 mg every 24 hours
Clcr <10 mL/minute: Administer 100-200 mg every 24 hours
Continuous arteriovenous or venovenous hemodiafiltration (CAVH) effects:
Administer 300 mg every 24 hours
|Mental Health: Effects
on Mental Status|
May cause drowsiness, dizziness, nervousness, or insomnia; quinolones
reported to cause restlessness, hallucinations, euphoria, depression, panic, and
Effects on Psychiatric
Inhibits CYP1A2 isoenzyme; use caution with clozapine and other
psychotropics; monitor for adverse effects
|Dental Health: Local
No information available to require special precautions
Effects on Dental Treatment|
No effects or complications reported
Oral: Take per recommended schedule; complete full course of therapy and do
not skip doses. Take on an empty stomach (1 hour before or 2 hours after meals,
dairy products, antacids, or other medication). Maintain adequate hydration (2-3
L/day of fluids unless instructed to restrict fluid intake).
Oral/I.V.: You may experience dizziness, lightheadedness (use caution when
driving or engaging in tasks that require alertness until response to drug is
known); nausea, vomiting, or taste perversion (small frequent meals, frequent
mouth care, sucking lozenges, or chewing gum may help); photosensitivity (use
sunscreen, wear protective clothing and eyewear, and avoid direct sunlight).
Report GI disturbances, CNS changes (excessive sleepiness, agitation, or
tremors), skin rash, changes in vision, difficulty breathing, signs of
opportunistic infection (sore throat, chills, fever, burning, itching on
urination, vaginal discharge, white plaques in mouth), or worsening of
condition. Pregnancy/breast-feeding precautions: Inform prescriber if
you are or intend to be pregnant. Do not breast-feed.
Ophthalmic: Tilt head back, instill 1-2 drops in affected eye as frequently
as prescribed. Do not allow tip of applicator to touch eye or any contaminated
surface. You may experience some stinging or burning or a bad taste in you mouth
after instillation. Report persistent pain, burning, swelling, or visual
Hold antacids for 2-4 hours before and after administering
Injection: 200 mg (50 mL); 400 mg (10 mL, 20 mL, 100 mL)
Ophthalmic: 0.3% (5 mL)
Otic: 0.3% (5 mL)
Tablet: 200 mg, 300 mg, 400 mg
" In vitro Activities of Ciprofloxacin, Levofloxacin, Lomefloxacin, Ofloxacin, Pefloxacin, Sparfloxacin, and Trovafloxacin Against Gram-Positive and Gram-Negative Pathogens From Respiratory Tract Infections,"
J Antimicrob Chemother, 1997, 40(3):427-31.
Hooper DC and Wolfson JS, "Fluoroquinolone Antimicrobial Agents," N Engl J
Med, 1991, 324(6):384-94.
Kohler RB, Arkins N, and Tack KJ,
"Accidental Overdose of Intravenous Ofloxacin With Benign Outcome,"
Antimicrob Agents Chemother, 1991, 35(6):1239-40.
Lomaestro BM and Bailie GR, "Quinolone-Cation Interactions: A Review,"
DICP, 1991, 25(11):1249-58.
Monk JP and Campoli-Richards DM,
"Ofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,"
Drugs, 1987, 33(4):346-91.
Nilsson-Ehle I and Ljungberg B,
"Quinolone Disposition in the Elderly: Practical Implications," Drugs
Aging, 1991, 1(4):279-88.
Stein GE, "The 4-Quinolone Antibiotics: Past, Present, and Future,"
Pharmacotherapy, 1988, 8(6):301-14.
Szarfman A, Chen M, and Blum MD,
"More on Fluoroquinolone Antibiotics and Tendon Rupture," N Engl J Med,
Thalhammer F, Kletzmayr J, El Menyawi I, et al,
"Ofloxacin Clearance During Hemodialysis: A Comparison of Polysulfone and Cellulose Acetate Hemodialyzers,"
Am J Kid Dis, 1998, 32(4):642-5.
U.S. Department of Health and Human Services,
"1993 Sexually Transmitted Diseases Treatment Guidelines," MMWR Morb Mortal
Wkly Rep, 1993, 42(RR-14).
Walker RC and Wright AJ, "The Fluoroquinolones," Mayo Clin Proc, 1991,
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved